Semaglutide: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. Semaglutide is discussed here as a research compound and is not approved by Health Canada for the research applications described in this guide.

Last updated: July 2026

---

Chances are you didn’t need an introduction to what semaglutide is — you needed to know whether it’s actually the right compound for your objective, what almost a decade of real-world use has taught us since it left the lab, and everything you’d need to know to run a first protocol confidently. That’s what this guide is built to do.

Quick Facts

Class	GLP-1 receptor agonist
Receptor targets	GLP-1
Administration	Once weekly, subcutaneous
Half-life	~7 days
Typical effective range	0.25mg–0.5mg weekly (community-reported)
Studied range	Up to 2.4mg weekly
Evidence tier	Very high — largest and longest human clinical dataset in its class
Regulatory status	Fully approved (Ozempic, Wegovy, Rybelsus)
First approved	2017

The Story So Far

The lineage here goes back further than most people realize. In the 1990s, researchers studying the venom of the Gila monster isolated a compound called exendin-4, which shared a structural resemblance to a human gut hormone called GLP-1. That discovery eventually led to exenatide, the first GLP-1 receptor agonist drug ever approved, and it opened the door to an entire drug class built on the same idea: mimic this hormone, extend how long it stays active in the body, and see what happens to appetite and blood sugar as a result. Semaglutide is a much later, fully synthetic descendant of that idea — engineered by Novo Nordisk rather than derived from the same natural source, but built on the same core insight.

Novo Nordisk’s SUSTAIN clinical trial program got underway around 2012. Five years later, in December 2017, the FDA approved the first version — Ozempic, for type 2 diabetes, at modest 0.5mg and 1mg doses. It arrived in Canada a month later, in the EU the month after that. For over three years, that’s all it was: a solid, unremarkable diabetes drug quietly accumulating a good safety record. Rybelsus, the oral tablet version, followed in September 2019, also for diabetes. In January 2020, Ozempic’s label expanded to include cardiovascular risk reduction, based on the SUSTAIN-6 trial — a genuinely important milestone, since it meant the drug wasn’t just neutral on heart health, it was measurably protective.

Then came June 2021, and Wegovy — a higher-dose formulation (2.4mg) approved specifically for weight management. This is the moment everything changed. A drug that had existed quietly for years was suddenly everywhere, and within two years “Ozempic” had become one of the most talked-about words in medicine, marketing, and casual conversation alike. The “overnight sensation” people remember from 2022 and 2023 was really the visible surface of a decade of unglamorous clinical work that had already happened.

The approvals kept coming after that. In January 2025, Ozempic gained an additional indication to reduce the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial. In March 2024, Wegovy’s label expanded to cover cardiovascular event reduction more broadly. In December 2025, an oral 25mg formulation of Wegovy was approved specifically for weight management — the first oral GLP-1 drug cleared for that use — launching in the U.S. in early 2026. As of this writing, that’s the most recent chapter in a regulatory story spanning nearly a decade, and it’s very likely not the last one.

What It Actually Does

Semaglutide copies a hormone your gut already makes after you eat, called GLP-1, and keeps it active in your system far longer than your body ever would on its own — about a week, instead of a few minutes. That extended signal does three things at once: it tells your brain you’re full sooner, it slows down how fast food leaves your stomach, and it helps your pancreas release insulin more effectively when blood sugar rises. None of this is a new mechanism your body hasn’t seen before — it’s an amplification of something it already does, which is a large part of why the side effect profile is generally more tolerable than older weight-management drugs that worked through blunter, less targeted mechanisms.

The reason it only needs to be injected once a week, rather than daily like the natural hormone would require, comes down to a deliberate engineering choice: semaglutide is attached to a fatty acid chain that binds to albumin in the blood, extending its active life from minutes to approximately seven days.

What the Research Shows

The evidence didn’t arrive all at once — it built in layers, each one adding a different piece of confidence, over almost a decade.

The earliest major signal was SUSTAIN-6 in 2016, a cardiovascular safety trial in 3,297 adults with type 2 diabetes and established heart disease. It found a 26% relative reduction in major adverse cardiovascular events compared to placebo — a genuinely reassuring finding for a new drug class at the time, and the basis for the January 2020 label expansion.

The real inflection point was the STEP trial program, published starting in 2021. STEP 1 enrolled nearly 2,000 participants without diabetes and found an average 14.9% body weight reduction at 68 weeks, compared to about 2.4% on placebo — a gap large enough to convince the broader medical and scientific community this wasn’t an incremental weight-loss aid, but a different category of intervention entirely. STEP 5 followed the same population out to two years and found the results held — 15.6% at week 52 and 15.2% at week 104, meaning very little regain occurred as long as treatment continued.

SELECT, published in 2023, took the cardiovascular question further, studying people with obesity and existing cardiovascular disease but without diabetes, and again found a meaningful reduction in major cardiac events. This mattered because it decoupled the cardiovascular benefit from diabetes status specifically — the protective effect wasn’t just a byproduct of better blood sugar control.

The FLOW trial, which supported the January 2025 kidney-disease indication, found a statistically significant 24% relative risk reduction in kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease — extending the evidence base into organ protection beyond the heart.

Most recently, a 2026 follow-up analysis of the SOUL trial (originally published in 2024, following nearly 9,650 participants with type 2 diabetes and cardiovascular or kidney disease for close to four years) specifically examined patients who already had heart failure, and found that oral semaglutide reduced heart failure hospitalizations and cardiovascular death in that population — addressing a group where earlier data had been more uncertain.

Taken together, this is arguably the deepest, most chronologically layered evidence base of any weight-management compound available today — not because any single trial is unusually large, but because the story has been building consistently for close to a decade, across different populations, with genuinely long follow-up windows.

How It Compares

Semaglutide sits in a category with two newer, more powerful compounds: tirzepatide and retatrutide. All three work on the same broad idea — hijacking gut-hormone signaling to control appetite and metabolism — but they’re meaningfully different tools, and the differences matter for deciding which one fits your research objective.

	Semaglutide	Tirzepatide	Retatrutide
Receptor targets	GLP-1 only	GLP-1 + GIP	GLP-1 + GIP + Glucagon
Approx. weight reduction (trial data)	~15% at 68 weeks (STEP 1)	~22.5% at 72 weeks (SURMOUNT-1)	~28.3% at 80 weeks (TRIUMPH-1, Phase 3)
Years of real-world data	~9 years (approved 2017)	~4 years (approved 2022)	Not yet approved; Phase 3 complete as of 2026
Cardiovascular outcome data	Extensive — SUSTAIN-6, SELECT, SOUL	Emerging, not yet as mature	None yet — too early in development
Kidney outcome data	Yes — FLOW trial	Not yet established	Not yet established
Regulatory status	Fully approved (multiple formulations)	Fully approved	Not yet submitted; NDA filing expected late 2026
Best evidence maturity for	Long-term cardiovascular and renal safety confidence	Balance of strong efficacy with a real approval history	Maximum documented efficacy, with the least real-world track record

The honest way to think about this category: potency has gone up with each newer compound, but evidence maturity has gone down. Semaglutide gives up some raw effectiveness in exchange for the deepest, longest, most independently replicated safety record of the three — including outcome data most drugs never get, like reduced kidney failure and reduced heart failure hospitalization. Tirzepatide sits in the middle: meaningfully more effective in head-to-head trials, with a shorter but still substantial approval history. Retatrutide currently has the most striking trial results of any compound in this category, but by definition, a compound that hasn’t been approved has no post-approval real-world data yet — its risk profile is still being established.

Neither more potent nor more established is objectively “better” — they answer different priorities. A researcher optimizing for maximum documented confidence in long-term organ and cardiovascular safety has good reason to be interested in semaglutide specifically. A researcher optimizing for the strongest effect size, and comfortable with a shorter track record, has good reason to look at the newer compounds instead.

Who Shouldn’t Use This

Some situations rule semaglutide out entirely, not just call for caution:

• Personal or family history of medullary thyroid carcinoma (MTC). This is an absolute contraindication. Semaglutide caused thyroid C-cell tumors in rodent studies, and while human relevance is unconfirmed, this is treated as a hard stop rather than a caution.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• History of pancreatitis.
• Severe gastrointestinal disease, including gastroparesis — the mechanism itself (slowed gastric emptying) can meaningfully worsen these conditions.
• Pregnancy or breastfeeding.

A few situations call for real caution and a conversation with a healthcare provider rather than an outright stop:

• Concurrent use of insulin or sulfonylureas. Semaglutide increases insulin release when blood sugar is elevated, and combining it with drugs that also lower blood sugar meaningfully raises the risk of hypoglycemia. This combination generally requires a dose adjustment to the other medication, not just added awareness.
• Any oral medication with a narrow therapeutic window or that depends on rapid absorption. Because semaglutide slows gastric emptying, it can change how quickly and completely other oral drugs are absorbed. This is a real interaction, not a theoretical one.
• History of gallbladder disease or gallstones. Rapid weight loss itself — not just semaglutide specifically — is an established risk factor for gallstone formation.
• Planned surgery within 30 days. Slowed gastric emptying carries a documented risk of pulmonary aspiration under general anesthesia or sedation. This is significant enough that many surgical and anesthesia guidelines now recommend pausing GLP-1 compounds before procedures.

If any of the above applies to you, this is exactly the kind of decision that belongs with a doctor, not with a research guide.

Common Myths, Addressed

“It’s just willpower in a needle.” Community and clinical reporting both consistently describe the appetite change as feeling qualitatively different from dieting — less like resisting temptation, more like genuinely not thinking about food the same way. The mechanism supports this: it’s a hormonal signal being amplified, not a behavioral intervention being imposed.

“You’ll lose all your muscle.” Some lean mass loss alongside fat loss is real and well-documented — it happens with essentially any significant caloric deficit, not uniquely with semaglutide. It’s a legitimate consideration, not a fabricated scare, but “all your muscle” overstates it considerably, and it’s manageable with adequate protein intake and resistance training.

“It stops working after a few months.” Plateaus are real and commonly discussed, but they’re not the same as the compound losing effect. STEP 5 found sustained results out to two full years of continued use, with minimal regain as long as treatment continued.

“Once you stop, you’ll gain it all back immediately.” Not immediate, but regain is real and well-documented — see “What Happens If You Stop,” below. This one is closer to true than the others, and worth taking seriously rather than dismissing.

“Semaglutide and Ozempic are different things.” They’re the same molecule. Ozempic, Wegovy, and Rybelsus are different products (different doses, indications, and in Rybelsus’s case, a different route), but the active compound is identical across all three.

What Researchers Are Actually Experiencing

Clinical trials describe what happens to the average participant under controlled conditions. They don’t describe what the first few weeks actually feel like, and that gap is where community research experience is genuinely useful.

The most consistent theme is that the early weeks are the hardest part, and that’s expected rather than a warning sign — mild nausea, a sharper-than-anticipated drop in appetite, and occasional fatigue are the most commonly reported early experiences, and they reliably ease for people who move through the titration schedule slowly rather than rushing it.

Plateaus come up often in community discussion, usually accompanied by concern that something has gone wrong. In most cases nothing has — weight loss in the STEP trials wasn’t perfectly linear either, and community-reported experience is that plateaus tend to resolve with time or a modest dose adjustment rather than requiring an aggressive escalation.

Lean mass loss is one of the more frequently discussed downsides, enough that it’s a major reason researchers frequently look into pairing GLP-1 protocols with growth-hormone-axis compounds aimed at preserving muscle during a caloric deficit — more on that below.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Titration Schedule

Phase	Weekly Dose	Duration
Titration	0.25mg	4 weeks
Titration	0.5mg	4 weeks
Titration	1mg	4 weeks
Active	1.7mg	4 weeks
Active	2.4mg	Ongoing research phase

Most researchers never make it past the second or third step, and don’t need to — real-world data from thousands of tracked community protocols consistently shows the majority find their effective range between 0.25mg and 0.5mg. The maximum studied dose exists in clinical trials as a ceiling, not a destination.

Hold your current dose if side effects haven’t resolved, if it’s been less than 4 weeks since your last increase, or if you’re already achieving your research objective. Consider lowering if side effects are meaningfully affecting your ability to eat or function normally — that’s a sign the dose is outpacing adaptation, not that the compound has failed. Only raise after a full 4 weeks at your current dose, once side effects have settled. Never increase dose to “catch up” after a missed week; resume at your last well-tolerated dose instead.

Worked Dose Math

At 5mg/mL (a 5mg vial reconstituted with 1mL BAC water, or a 10mg vial with 2mL):

• 0.25mg → 0.05mL → 5 units
• 0.5mg → 0.1mL → 10 units
• 1mg → 0.2mL → 20 units
• 2.4mg → 0.48mL → 48 units (close to half a syringe — double-check this one specifically)

The underlying rule: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe.

Vial Planning

A 10mg vial at 5mg/mL gives you 10mg total. At a steady 0.5mg/week, that’s roughly 20 weeks per vial. At 2.4mg/week, closer to 4 weeks. Worth doing this math before ordering so your vial size actually matches your protocol length. For the full reconstitution walkthrough and math for every vial size and concentration, see our dedicated reconstitution guide.

Reconstitution and Storage — The Short Version

Semaglutide follows the standard approach used across nearly every compound in this series: reconstitute with BAC water, refrigerate at 2–8°C, and use within 28 days. Nothing about semaglutide specifically deviates from this. For the complete reconstitution process, storage principles, and troubleshooting, see our dedicated guide.

Sourcing

There’s nothing semaglutide-specific to add here beyond what applies to any research peptide — see our full guide on reading a Certificate of Analysis and vetting a vendor for the complete picture.

Administration

Once weekly subcutaneous injection, same day each week, standard site rotation (abdomen, thigh, or upper arm). No fasting requirement.

Best Practices

• Hydrate consistently, especially during titration — GI side effects and reduced food/fluid intake together raise dehydration risk more than either factor alone.
• Prioritize protein intake at each meal to help preserve lean mass during a caloric deficit — this matters more here than in most weight-management contexts, precisely because appetite suppression can make it easy to under-eat protein without noticing.
• Consider electrolytes, particularly if GI side effects include vomiting or diarrhea, or if food intake drops significantly during the early weeks.
• Eat smaller, more frequent meals if nausea or early satiety is significant — this is one of the most consistently reported practical fixes in community discussion.
• Track your protocol from day one. At minimum: dose, injection date, weight or measurements, and any side effects. This is what makes plateaus, side effects, and progress interpretable instead of anecdotal, even to yourself.

Common Mistakes to Avoid

• Rushing the titration schedule to reach results faster — the single most common cause of severe GI side effects and early discontinuation.
• Not recording the reconstitution volume, turning every future dose calculation into a guess.
• Assuming a plateau means the compound has stopped working and escalating dose aggressively in response, rather than giving it time or making a modest adjustment.
• Heavy alcohol use, which can compound GI side effects and dehydration risk, particularly during titration.
• Under-eating protein because appetite suppression makes it easy not to notice you’re doing it.

What Happens If You Stop

This is worth knowing before you start, not after. The STEP 1 trial extension followed participants for a year after they stopped semaglutide and found they regained an average of 11.6 percentage points of the 17.3% they’d lost — roughly two-thirds of their total weight loss — with most cardiometabolic improvements reverting toward baseline as well. The STEP 4 trial found a similar pattern over a shorter window: participants who switched to placebo after an initial run-in period gradually regained weight, while those who continued treatment kept losing and then plateaued.

The consensus from this data is consistent: semaglutide’s effects are maintained by continued use, not “cured” by a period of use — similar to how blood pressure medication controls blood pressure only while it’s being taken. This isn’t a flaw specific to semaglutide; it reflects the chronic, relapsing nature of the underlying appetite and metabolic regulation it acts on. Go in with a realistic plan for the end of a protocol, not just the beginning.

If you do restart after a gap, restart at the beginning of the titration schedule — tolerance for higher doses isn’t preserved during time off.

What to Expect, Week by Week

• Weeks 1–4 (0.25mg): Often minimal noticeable weight change; this phase is about tolerability, not results. Mild GI symptoms are most common here.
• Weeks 5–12 (0.5mg–1mg): Appetite suppression becomes more noticeable for most researchers. Early, gradual weight change typically begins here.
• Weeks 13–20 (1.7mg): For those continuing to titrate, this is often where the balance between side effects and results becomes clearer.
• Week 20 onward: Many researchers settle into an effective dose for months at a time. Consistent results with occasional plateaus is the realistic long-term pattern, not a smooth continuous decline.

Individual timelines vary substantially — this is a general pattern, not a guarantee.

Combining With Other Compounds

Lean mass loss is one of the most commonly discussed drawbacks of GLP-1 research, and it’s a major reason GH-axis compounds — particularly CJC-1295 paired with Ipamorelin — come up frequently in the same conversations as semaglutide. The rationale is straightforward: a GLP-1 compound creates a caloric deficit, and a GH secretagogue supports lean mass preservation during that deficit. If body composition, not just total weight change, is your research objective, this combination is worth researching in its own depth before combining anything.

Common Questions

Is semaglutide the same as Ozempic? Yes — different product names for the same molecule, differing in dose, indication, and formulation.

Why does titration speed matter so much? GI side effects are dose-dependent and tied to how quickly the digestive system adapts to slower gastric emptying. Rushing the schedule is the single most common reason researchers discontinue early.

How does it compare to tirzepatide and retatrutide in plain terms? Less potent, but far more established. If maximum documented safety history matters more than maximum effect size, semaglutide is the more conservative choice of the three.

Is oral semaglutide as effective as the injectable version? Not currently — oral Wegovy showed 13.6% weight loss at 64 weeks versus roughly 15% for injectable Wegovy at a similar duration, largely due to lower and less consistent absorption through the digestive tract.

What happens if I stop and then want to restart later? Restart at the beginning of the titration schedule, not at your previous dose — tolerance isn’t preserved during time off.

Can I drink alcohol while researching this compound? Occasional, moderate use isn’t specifically contraindicated, but alcohol can compound GI side effects and dehydration risk, particularly during titration.

Before You Start

A quick checklist to run through before your first dose:

• Confirmed none of the absolute contraindications apply to you
• Reviewed current medications for potential interactions, especially insulin or sulfonylureas
• Have your titration schedule and vial size planned together
• Have a tracking method ready for dose, injection date, and side effects
• Understand that plateaus are normal, not a failure signal
• Thought through what happens at the end of your protocol, not just the start

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Phase	Dose	Frequency
Titration start	0.25mg	Once weekly
Titration	0.5mg	Once weekly
Titration	1mg	Once weekly
Active	1.7mg	Once weekly
Active	2.4mg	Once weekly
Typical effective range (community-reported)	0.25mg–0.5mg	Once weekly

Where to Go From Here

• Semaglutide vs. Tirzepatide vs. Retatrutide — full category comparison
• How to Manage GLP-1 Side Effects — nausea, fatigue, and GI strategies in depth
• Preserving Lean Mass During a GLP-1 Protocol — protein, training, and stacking
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.